Table 1.
Baseline characteristics of all patients with complete analyses of meth-ctDNA (n = 123).
| Parameter | All patients | Meth-ctDNA zero at T0 (n = 16) |
Elevated meth-ctDNA at T0 (n = 107) |
p values comparing the two groups |
|---|---|---|---|---|
| n (%) | n (% of all patients) | n (% of all patients) | ||
| Age, years | ||||
| Median (range) | 67 (32–80) | 69 (50–77) | 67 (32–80) | ns |
| Gender | ||||
| Female | 45 (37) | 6 (38) | 39 (36) | ns |
| Male | 78 (63) | 10 (63) | 68 (64) | |
| PS | ||||
| 0–1 | 117 (95) | 15 (94) | 102 (95) | ns |
| 2 | 6 (5) | 1 (6) | 5 (5) | |
| Location of primary tumor | ||||
| Right/transverse colon | 32 (26) | 2 (13) | 30 (28) | |
| Left colon | 40 (33) | 6 (38) | 34 (32) | ns |
| Rectum | 51 (41) | 8 (50) | 43 (40) | |
| Primary disseminated disease | 99 (80) | 11 (69) | 88 (82) | ns |
| Recurrent disease | 24 (20) | 5 (4) | 19 (15) | |
| RAS/RAF mutated tumor | 63 (50)* | 13 (11) | 50 (42) | – |
| Number of metastatic sites | ||||
| ⩽2 | 97 (79) | 15 (94) | 82 (77) | ns |
| >2 | 26 (21) | 1 (6) | 25 (23) | |
meth-ctDNA, hypermethylated neuropeptide Y (NPY) circulating tumor DNA; n, number; ns, non-significant; PS, performance status.
*
11 Patients did not have their tumor tissue analyzed due to insufficient material.